Skip to content

ANNOUNCING A UNIQUE J-CODE FOR MONJUVI J9349 EFFECTIVE APRIL 1, 2021 Monjuvi, tafasitamab-cxix, 2mg, for injection, for intravenous use


On behalf of MorphoSys US Inc. and Incyte Corporation, I am pleased to announce that a permanent J-Code, J9349, is now available for MONJUVI, effective on April 1, 2021. On July 31, 2020, the US Food and Drug Administration (FDA) approved MONJUVI.

In the table below, you’ll find some important information about the MONJUVI J-Code, as well as links to other useful information.

MONJUVI Permanent J-Code Information



Effective Date

April 1, 2021

J-Code Unit Descriptor

Injection, tafasitamab-cxix, 2mg

Single-Dose Vial Size


Billing Unit Conversion

One 200mg Single-Dose Vial = 100 Units

National Drug Code (NDC)


Prescribing Information

Prescribing Information

FDA Approval Information

FDA Approval Letter

Wholesale Acquisition Cost (WAC)

$1,200 / Vial established August 2020

We are providing the information above to help support any claims system and processing updates that are necessary to accommodate the new J-Code for MONJUVI, J9349, effective April 1, 2021. We will be following up with you to answer any questions that you may have and to ensure that the new MONJUVI J-Code is reflected in your system.

Powered By GrowthZone